Screening for ovarian, prostatic, and testicular cancers.
Screening for cancer should not be offered routinely to a symptomatic people on a population basis unless it has been shown to be effective in reducing mortality in randomised controlled trials. A suitable screening test should have high sensitivity and specificity and a high positive predictive value. There is an ethical imperative to ensure that the benefit to each person from screening is likely to outweight the possible harm. Preliminary studies have identified suitable screening tests for ovarian cancer, and a randomised controlled trail is about to start. There is considerable controversy about whether to screen for prostatic cancer. Likewise, there is uncertainty about the best means of treating localised prostatic cancer. Screening for prostatic cancer raises important ethical considerations which should not be ignored. Testicular self examination is of unproved benefit. Although there is a need for education about the early signs and symptoms of testicular cancer to reduce delay at presentation, a case cannot be made for screening.
Austoker
J
J
Department of Public Health and Primary Care, University of Oxford.
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D005260:Female; D006293:Health Promotion; D006801:Humans; D008297:Male; D008403:Mass Screening; D010051:Ovarian Neoplasms / Q000517:prevention & control*; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D012680:Sensitivity and Specificity; D013736:Testicular Neoplasms / Q000517:prevention & control*; D006113:United Kingdom
D015295:Antigens, Tumor-Associated, Carbohydrate; D017430:Prostate-Specific Antigen